Peloton Therapeutics, Inc.

Array Biopharma Inc.

Astrazeneca Ab

Intermune, Inc.

Genentech, Inc.

University of Colorado

Bin Wang

Eli M Wallace

James P Rizzi

Peter J Mohr

Hanbiao Yang

Michael Lyon

Paul Wehn

James F Blake

Stephen T Schlachter

Rui Xu

John A Josey

Yvan Le Huerou

Jonas Grina

Darryl David Dixon

Indrani W Gunawardana

Mark Joseph Chicarelli

Tao Wang

Michelle Lamb

Dingwei Yu

Steven Wade Andrews

Yutong Jiang

Timothy S Kercher

Scott D Seiwert

Lawrence M Blatt

April L Kennedy

Robert J Kaus

Pierre Martin

Paul Nichols

Weidong Liu

Paul D Lyne

Andreas Schumacher

C Todd Eary

Tarek Sammakia

Karl Bedke

Bradley Barnett

Leonid Beigelman

Brad Owen Buckman

Kevin Ronald Condroski

Stephanos Ioannidis

John E Robinson

Yongxin Han

Henry C Kapteyn

Margaret Mary Murnane

Huiping Guan

Robert Kirk Delisle

Bo Peng

James M Graham

Audrey Davies

Mei Su

Ying Kan

Ying Kang

Hai-Jun Zhang

Lisa A De Meese

Pete Mohr

Xiaomei Feng

Indrani W Gunwardana

Audrey Molina

Chen-Ting Liao

Heli Huang

Keshi Wang

Paul Lyne

Compounds that modulate CD73 activity, pharmaceutical compositions containing these compounds, and methods of using these compounds for treating diseases associated with CD73 activity are described herein.

Compositions and methods for inhibiting CD73

Apparatus and methods for coherent diffraction imaging. This is accomplished by acquiring data in a CDI setup with a CMOS or similar detector. The object is illuminated with coherent light such as EUV light which may be pulsed. This generates diffraction patterns which are collected by the detector, either in frames or continuously (by recording the scan position during collection). Pixels in the CDI data are thresholded and set to zero photons if the pixel is below the threshold level. Pixels above the threshold may be set to a value indicating one photon, or multiple thresholds may be used to set pixels values to one photon, two photons, etc. In addition, multiple threshold values may be used to detect different photon energies for illumination at multiple wavelengths.

Quantum-limited extreme ultraviolet coherent diffraction imaging

The present disclosure relates to HIF-2α inhibitors and methods of making and using them for treating cancer. Certain compounds were potent in HIF-2α scintillation proximity assay, luciferase assay, and VEGF ELISA assay, and led to tumor size reduction and regression in 786-O xenograft bearing mice in vivo.

Aryl ethers and uses thereof

The present disclosure provides compounds of Formula (II)  wherein R, R, R, R, R, W, W, W, X, Y, and A are as described herein. The disclosed compounds modulate CD73 activity. The present disclosure also provides, pharmaceutical compositions containing these compounds, and methods of using these compounds for treating diseases associated with CD73 activity.

CD73 inhibitors and uses thereof

Disclosed herein are substituted indane derivatives useful as HIF-2&#x3b1; inhibitors. Pharmaceutical compositions comprising said indane derivatives and methods of using said indane derivatives for treating proliferative diseases, such as renal cell carcinoma and von Hippel-Lindau disease, and other conditions associated with HIF-2&#x3b1; activity are also disclosed.

Aromatic compounds and uses thereof

The present disclosure relates to HIF-2&#x3b1; inhibitors and methods of making and using them for treating cancer. Certain compounds were potent in HIF-2&#x3b1; scintillation proximity assay, luciferase assay, and VEGF ELISA assay, and led to tumor size reduction and regression in 786-O xenograft bearing mice in vivo.

Benzimidazole derivatives of Formula I, that modulate the activity of ACSS2 are disclosed for therapeutic use. The fused imidazole ring of the compounds disclosed has a diarylmethyl or diarylmethanol moiety attached at the 2-position and the as compounds have at least one other substituent at the 5 or 6 position of the benzimidazole. Also disclosed are methods of using the benzimidazole compounds for the treatment of diseases or disorders, such as cancer.

Benzimidazole derivatives and uses thereof

Compounds of Formula I are useful for inhibition of CHK1 and/or CHK2. Methods of using compounds of Formula I and stereoisomers and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed. 

Pyrrolopyridines as kinase inhibitors

The present disclosure relates to cyclic sulfones and sulfoximines that are HIF-2a inhibitors and methods of making and using them for treating cancers. In another aspect, the present disclosure provides a pharmaceutical composition comprising a compound described herein and a pharmaceutically acceptable carrier or excipient. The compound may exist in an amorphous form, a crystalline form, or as a salt, solvate, or hydrate. In another aspect, the present disclosure provides a method of treating renal cell carcinoma by administrating a therapeutically effective amount of a compound described herein or a pharmaceutical composition thereof to a subject in need of such treatment.

Cyclic sulfone and sulfoximine analogs and uses thereof

Growing community of inventors

Boulder, CO, United States of America

Bin Wang